MTND4P20

Across TCGA pan-cancer cohorts, MTND4P20 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of MTND4P20’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MTND4P20 RNA is repressed in tumor relative to normal tissue. In most cancer types MTND4P20 is over-expressed in tumor, although a few such as LIHC and KICH show the opposite, repressed pattern.

LIHC, KICH, and KIRP are the cancer types where MTND4P20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTND4P20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	−1.750	<.001	7	view →
KICH	All	All	−0.178	<.001	7	view →
KIRP	All	All	+0.452	.002	6	view →
BRCA	All	All	−0.105	<.001	6	view →
KIRC	Male	All	+0.232	.018	4	view →
CHOL	All	All	−3.335	<.001	3	view →
PAAD	All	All	+2.114	.012	2	view →
UCEC	All	All	+0.127	.017	2	view →
COAD	Female	All	−0.612	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

MTND4P20–LIHC

Open the LIHC breakdown →